Expanding a Brand: Statins and PPAR-Gamma Agonists to Treat Neurological Disease

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Opportunity in Neurological Disease Markets
• The Alzheimer' s Disease Market
• The Multiple Sclerosis Market
• The Use of Statins in Treating Alzheimer' s Disease
• Pathophysiology of Alzheimer' s Disease
• Statins' Potential Effect on Alzheimer' s Disease
• Clinical Support for Statin Use in Treating Alzheimer' s Disease
• Commercial Interest in Developing Statins for Alzheimer' s Disease
• The Use of Statins in Treating Multiple Sclerosis
• Pathophysiology of Multiple Sclerosis
• Statins' Potential Effect on Multiple Sclerosis
• Clinical Support for Statin Use in Multiple Sclerosis
• Commercial Interest in the Development of Statins for Multiple Sclerosis
• The Use of PPAR-Gamma Agonists in the Treatment of Alzheimer' s Disease
• Potential Effect on Alzheimer' s Disease
• Clinical Support for PPAR-Gamma Agonists in Alzheimer' s Disease
• Commercial Interest in Developing PPAR-Gamma Agonists for Alzheimer' s Disease
• Outlook

Tables

• 1. Leading Agents to Treat Alzheimer' s Disease in the Major Pharmaceutical Markets, 2005
• 2. Leading Agents to Treat Multiple Sclerosis in the Major Pharmaceutical Markets, 2005
• 3. Pfizer' s Lipitor: A Fact Sheet
• 4. Clinical Trials Investigating the Use of Statins to Treat Multiple Sclerosis
• 5. Pfizer' s Top-Selling Products, 2005

Figures

• 1. Sales of Agents to Treat Alzheimer' s Disease, 2005-2010
• 2. Sales of Agents to Treat Multiple Sclerosis, 2005-2010